{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:36:15Z","timestamp":1793900175310,"version":"4.8.0"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cancer treatments like chemotherapy, radiotherapy, and combined immunotherapies have significantly increased patient survival. However, these treatments are frequently linked to cardiovascular toxicity, which has a significant impact on clinical outcomes and patient well-being. Chemotherapy, targeted therapy, and radiotherapy induce significant cellular stress in cardiomyocytes and endothelial cells, causing DNA damage, activating pro-inflammatory and pro-apoptotic signalling pathways. Cumulative damage causes cardiomyocyte loss, followed by fibrosis, resulting in pathological structural and functional remodelling of the myocardium. Endothelial cell damage disrupts vascular integrity, increasing the risk of atherosclerosis, coronary artery disease, and ischaemia. Over time, these changes can lead to clinical conditions like dilated and restrictive cardiomyopathy, which are frequently accompanied by arrhythmias and can result in heart failure and sudden cardiac death. To overcome this problem, the novel field of cardio-oncology aims to provide effective cancer treatments with a multifaceted cardioprotection approach involving pharmacological, diagnostic, natural compounds, and lifestyle interventions during and after cancer therapy. In this review, we cover the important cancer therapies, and their cardiotoxic mechanisms and detail different cardioprotective strategies aimed at mitigating these adverse effects and improve patient outcomes.<\/jats:p>","DOI":"10.1007\/s10741-025-10531-0","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T03:58:13Z","timestamp":1749268693000},"page":"1075-1092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Cancer therapy-induced cardiotoxicity: mechanisms and mitigations"],"prefix":"10.1007","volume":"30","author":[{"given":"Solanki","family":"Shil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabodh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamalesh Dattaram","family":"Mumbrekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"6","key":"10531_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.mcna.2017.06.003","volume":"101","author":"N Gegechkori","year":"2017","unstructured":"Gegechkori N, Haines L, Lin JJ (2017) Long Term and Latent Side Effects of Specific Cancer Types. Med Clin North Am 101(6):1053\u20131073","journal-title":"Med Clin North Am"},{"issue":"4","key":"10531_CR2","first-page":"309","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D et al (2016) Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 66(4):309\u2013325","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"10531_CR3","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer. J Clin Oncol 25(25):3808\u20133815","journal-title":"J Clin Oncol"},{"issue":"12","key":"10531_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1200\/JCO.2013.51.1055","volume":"32","author":"GT Armstrong","year":"2014","unstructured":"Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM et al (2014) Aging and Risk of Severe, Disabling, Life-Threatening, and Fatal Events in the Childhood Cancer Survivor Study. J Clin Oncol 32(12):1218\u20131227","journal-title":"J Clin Oncol"},{"issue":"31","key":"10531_CR5","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V et al (2005) Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment. J Clin Oncol 23(31):7820\u20137826","journal-title":"J Clin Oncol"},{"key":"10531_CR6","unstructured":"American College of Cardiology [Internet]. [cited 2025 Jan 17]. Type I and Type II Cardiomyopathy Classifications Are Complete Nonsense: PRO. Available from: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2018\/05\/04\/08\/41\/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2018%2f05%2f04%2f08%2f41%2ftype-i-and-type-ii-cardiomyopathy-classifications-are-complete-nonsense-pro"},{"issue":"13","key":"10531_CR7","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","volume":"105","author":"DB Sawyer","year":"2002","unstructured":"Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105(13):1551\u20131554","journal-title":"Circulation"},{"issue":"15","key":"10531_CR8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","volume":"34","author":"TM Suter","year":"2013","unstructured":"Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart J 34(15):1102\u20131111","journal-title":"Eur Heart J"},{"issue":"1","key":"10531_CR9","first-page":"59","volume":"8","author":"M Florescu","year":"2013","unstructured":"Florescu M, Cinteza M, Vinereanu D (2013) Chemotherapy-induced Cardiotoxicity. Maedica 8(1):59\u201367","journal-title":"Maedica"},{"issue":"1","key":"10531_CR10","first-page":"8","volume":"1","author":"DK Shakir","year":"2009","unstructured":"Shakir DK, Rasul KI (2009) Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management. J Clin Med Res 1(1):8\u201312","journal-title":"J Clin Med Res"},{"issue":"4","key":"10531_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova M, Russell R (2011) Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Curr. Cardiol Rev 7(4):214\u2013220","journal-title":"Cardiol Rev"},{"issue":"12","key":"10531_CR12","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/ejhf.1985","volume":"22","author":"JL Zamorano","year":"2020","unstructured":"Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ et al (2020) The cancer patient and cardiology. Eur J Heart Fail 22(12):2290\u20132309","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10531_CR13","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","volume":"40","author":"P Lancellotti","year":"2019","unstructured":"Lancellotti P, Suter TM, L\u00f3pez-Fern\u00e1ndez T, Galderisi M, Lyon AR, Van der Meer P et al (2019) Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J 40(22):1756\u20131763","journal-title":"Eur Heart J"},{"issue":"41","key":"10531_CR14","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 43(41):4229\u20134361","journal-title":"Eur Heart J"},{"issue":"1","key":"10531_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.15420\/ecr.2017:17:2","volume":"13","author":"A Koutsoukis","year":"2018","unstructured":"Koutsoukis A, Ntalianis A, Repasos E, Kastritis E, Dimopoulos MA, Paraskevaidis I (2018) Cardio-oncology: A Focus on Cardiotoxicity. Eur Cardiol Rev 13(1):64\u201369","journal-title":"Eur Cardiol Rev"},{"issue":"9","key":"10531_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","volume":"12","author":"MS Ewer","year":"2015","unstructured":"Ewer MS, Ewer SM (2015S) Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12(9):547\u2013558","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10531_CR17","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin. Cancer 97(11):2869\u20132879","journal-title":"Cancer"},{"issue":"1","key":"10531_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1021\/tx9003424","volume":"23","author":"P Menna","year":"2010","unstructured":"Menna P, Salvatorelli E, Minotti G (2010) Anthracycline Degradation in Cardiomyocytes: A Journey to Oxidative Survival. Chem Res Toxicol 23(1):6\u201310","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"10531_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.14797\/mdcj-15-4-243","volume":"15","author":"TA Agunbiade","year":"2019","unstructured":"Agunbiade TA, Zaghlol RY, Barac A (2019) Heart Failure in Relation to Anthracyclines and Other Chemotherapies. Methodist DeBakey Cardiovasc J 15(4):243\u2013249","journal-title":"Methodist DeBakey Cardiovasc J"},{"issue":"10","key":"10531_CR20","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1042\/CS20200301","volume":"135","author":"A Narezkina","year":"2021","unstructured":"Narezkina A, Narayan HK, Zemljic-Harpf AE (2021) Molecular mechanisms of anthracycline cardiovascular toxicity. Clin Sci 135(10):1311\u20131332","journal-title":"Clin Sci"},{"issue":"19","key":"10531_CR21","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.3390\/jcm10194426","volume":"10","author":"M Jurczyk","year":"2021","unstructured":"Jurczyk M, Kr\u00f3l M, Midro A, Kurnik-\u0141ucka M, Poniatowski A, Gil K (2021) Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management. J Clin Med 10(19):4426","journal-title":"J Clin Med"},{"issue":"3","key":"10531_CR22","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1634\/theoncologist.2019-0762","volume":"25","author":"I Raber","year":"2020","unstructured":"Raber I, Warack S, Kanduri J, Pribish A, Godishala A, Abovich A et al (2020) Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study. Oncologist 25(3):e606\u2013e609","journal-title":"Oncologist"},{"issue":"1","key":"10531_CR23","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1186\/s12885-024-12981-5","volume":"24","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, de Almeida Barbosa AB, Sano VKT, Kelly FA, Burbano RMR (2024) Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis. BMC Cancer 24(1):1210","journal-title":"BMC Cancer"},{"key":"10531_CR24","doi-asserted-by":"crossref","unstructured":"Ardizzone A, Bulzom\u00ec M, De Luca F, Silvestris N, Esposito E, Capra AP. Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients. Curr Issues Mol Biol. 2024 Sep;46(9):9831\u201343.","DOI":"10.3390\/cimb46090584"},{"issue":"9","key":"10531_CR25","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","volume":"9","author":"EK Rowinsky","year":"1991","unstructured":"Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC (1991) Cardiac disturbances during the administration of taxol. J Clin Oncol 9(9):1704\u20131712","journal-title":"J Clin Oncol"},{"issue":"4","key":"10531_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000471759","volume":"12","author":"M Osman","year":"2017","unstructured":"Osman M, Elkady M (2017) A Prospective Study to Evaluate the Effect of Paclitaxel on Cardiac Ejection Fraction. Breast Care 12(4):255\u2013259","journal-title":"Breast Care"},{"issue":"5 Suppl 11","key":"10531_CR27","first-page":"23","volume":"23","author":"P Dombernowsky","year":"1996","unstructured":"Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV (1996) Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23(5 Suppl 11):23\u201327","journal-title":"Semin Oncol"},{"issue":"1","key":"10531_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","volume":"650","author":"ESE El-Awady","year":"2011","unstructured":"El-Awady ESE, Moustafa YM, Abo-Elmatty DM, Radwan A (2011) Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol 650(1):335\u2013341","journal-title":"Eur J Pharmacol"},{"key":"10531_CR29","doi-asserted-by":"crossref","unstructured":"Iqubal A, Iqubal MK, Sharma S, Ansari MohdA, Najmi AK, Ali SM, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sci. 2019 Feb 1;218:112\u201331.","DOI":"10.1016\/j.lfs.2018.12.018"},{"issue":"37","key":"10531_CR30","volume":"1","author":"D Valiyaveettil","year":"2023","unstructured":"Valiyaveettil D, Joseph D, Malik M (2023) Cardiotoxicity in breast cancer treatment: Causes and mitigation. Cancer Treat Res Commun 1(37)","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10531_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-021-00265-1","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam I, Swain SM (2021) HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. Npj Breast Cancer 7(1):1\u201312","journal-title":"Npj Breast Cancer"},{"issue":"10","key":"10531_CR32","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1161\/CIRCRESAHA.112.267286","volume":"111","author":"O Odiete","year":"2012","unstructured":"Odiete O, Hill MF, Sawyer DB (2012O 26) Neuregulin in Cardiovascular Development and Disease. Circ Res 111(10):1376\u20131385","journal-title":"Circ Res"},{"issue":"7","key":"10531_CR33","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.yexcr.2009.02.001","volume":"315","author":"L Pentassuglia","year":"2009","unstructured":"Pentassuglia L, Graf M, Lane H, Kuramochi Y, Cote G, Timolati F et al (2009A 15) Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res 315(7):1302\u20131312","journal-title":"Exp Cell Res"},{"issue":"7","key":"10531_CR34","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/02841860903229124","volume":"48","author":"GS Orphanos","year":"2009","unstructured":"Orphanos GS, Ioannidis GN, Ardavanis AG (2009) Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 48(7):964\u2013970","journal-title":"Acta Oncol"},{"issue":"5","key":"10531_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","volume":"7","author":"T Force","year":"2007","unstructured":"Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7(5):332\u2013344","journal-title":"Nat Rev Cancer"},{"issue":"9604","key":"10531_CR36","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet 370(9604):2011\u20132019","journal-title":"The Lancet"},{"issue":"28","key":"10531_CR37","doi-asserted-by":"publisher","first-page":"7135","DOI":"10.1200\/JCO.2005.16.139","volume":"23","author":"DR D\u2019Adamo","year":"2005","unstructured":"D\u2019Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K et al (2005) Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas. J Clin Oncol 23(28):7135\u20137142","journal-title":"J Clin Oncol"},{"key":"10531_CR38","doi-asserted-by":"crossref","unstructured":"Dobbin SJH, Petrie MC, Myles RC, Touyz RM, Lang NN (2021) Cardiotoxic effects of angiogenesis inhibitors. Clin Sci Lond Engl 1979. 135(1):71\u2013100.","DOI":"10.1042\/CS20200305"},{"issue":"10","key":"10531_CR39","doi-asserted-by":"publisher","first-page":"1093383","DOI":"10.3389\/fcvm.2023.1093383","volume":"6","author":"J Xiao","year":"2023","unstructured":"Xiao J, Li X, Wang X, Guan Y, Liu H, Liang J et al (2023) Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience. Front Cardiovasc Med 6(10):1093383","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10531_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645245","volume":"27","author":"J Hu","year":"2021","unstructured":"Hu J, Tian R, Ma Y, Zhen H, Ma X, Su Q et al (2021) Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis. Front Oncol 27(11)","journal-title":"Front Oncol"},{"issue":"16","key":"10531_CR41","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM et al (2018) Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 71(16):1755\u20131764","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10531_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2174\/1874467211666180219102520","volume":"11","author":"M Cheki","year":"2018","unstructured":"Cheki M, Yahyapour R, Farhood B, Rezaeyan A, Shabeeb D, Amini P et al (2018) COX-2 in Radiotherapy: A Potential Target for Radioprotection and Radiosensitization. Curr Mol Pharmacol 11(3):173\u2013183","journal-title":"Curr Mol Pharmacol"},{"issue":"8","key":"10531_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-021-00868-7","volume":"22","author":"P Ell","year":"2021","unstructured":"Ell P, Martin JM, Cehic DA, Ngo DTM, Sverdlov AL (2021) Cardiotoxicity of Radiation Therapy: Mechanisms, Management, and Mitigation. Curr Treat Options Oncol 22(8):70","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"10531_CR44","doi-asserted-by":"publisher","first-page":"6272","DOI":"10.3390\/ijms24076272","volume":"24","author":"KC Siaravas","year":"2023","unstructured":"Siaravas KC, Katsouras CS, Sioka C (2023) Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review. Int J Mol Sci 24(7):6272","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10531_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3857\/roj.2021.00766","volume":"40","author":"S Ellahham","year":"2022","unstructured":"Ellahham S, Khalouf A, Elkhazendar M, Dababo N, Manla Y (2022) An overview of radiation-induced heart disease. Radiat Oncol J 40(2):89\u2013102","journal-title":"Radiat Oncol J"},{"issue":"2","key":"10531_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172803","volume":"12","author":"MC Asensio-L\u00f3pez","year":"2017","unstructured":"Asensio-L\u00f3pez MC, Soler F, Pascual-Figal D, Fern\u00e1ndez-Belda F, Lax A (2017) Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS ONE 12(2)","journal-title":"PLoS ONE"},{"issue":"2","key":"10531_CR47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/toxsci\/kfr298","volume":"125","author":"A Strigun","year":"2012","unstructured":"Strigun A, Wahrheit J, Niklas J, Heinzle E, Noor F (2012) Doxorubicin Increases Oxidative Metabolism in HL-1 Cardiomyocytes as Shown by 13C Metabolic Flux Analysis. Toxicol Sci 125(2):595\u2013606","journal-title":"Toxicol Sci"},{"issue":"2","key":"10531_CR48","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00441-012-1475-8","volume":"350","author":"P Dimitrakis","year":"2012","unstructured":"Dimitrakis P, Romay-Ogando MI, Timolati F, Suter TM, Zuppinger C (2012) Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes. Cell Tissue Res 350(2):361\u2013372","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10531_CR49","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1038\/s41598-017-06385-8","volume":"7","author":"L Polonchuk","year":"2017","unstructured":"Polonchuk L, Chabria M, Badi L, Hoflack JC, Figtree G, Davies MJ et al (2017) Cardiac spheroids as promising in vitro models to study the human heart microenvironment. Sci Rep 7(1):7005","journal-title":"Sci Rep"},{"issue":"2","key":"10531_CR50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacbts.2017.12.007","volume":"3","author":"R Truitt","year":"2018","unstructured":"Truitt R, Mu A, Corbin EA, Vite A, Brandimarto J, Ky B et al (2018) Increased Afterload Augments Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model. JACC Basic Transl Sci 3(2):265\u2013276","journal-title":"JACC Basic Transl Sci"},{"issue":"5","key":"10531_CR51","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jaccao.2024.07.012","volume":"6","author":"KD Shead","year":"2024","unstructured":"Shead KD, Huethorst E, Burton F, Lang NN, Myles RC, Smith GL (2024) Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology. JACC CardioOncology 6(5):678\u2013683","journal-title":"JACC CardioOncology"},{"issue":"6","key":"10531_CR52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/cells7060048","volume":"7","author":"A Di Baldassarre","year":"2018","unstructured":"Di Baldassarre A, Cimetta E, Bollini S, Gaggi G, Ghinassi B (2018) Human-Induced Pluripotent Stem Cell Technology and Cardiomyocyte Generation: Progress and Clinical Applications. Cells 7(6):48","journal-title":"Cells"},{"issue":"10","key":"10531_CR53","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1161\/RES.0000000000000291","volume":"125","author":"G Gintant","year":"2019","unstructured":"Gintant G, Burridge P, Gepstein L, Harding S, Herron T, Hong C et al (2019) Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing. Circ Res 125(10):e75-92","journal-title":"Circ Res"},{"issue":"15","key":"10531_CR54","doi-asserted-by":"publisher","first-page":"1475152","DOI":"10.3389\/fphys.2024.1475152","volume":"12","author":"J Joshi","year":"2024","unstructured":"Joshi J, Albers C, Smole N, Guo S, Smith SA (2024) Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for modeling cardiac arrhythmias: strengths, challenges and potential solutions. Front Physiol 12(15):1475152","journal-title":"Front Physiol"},{"issue":"1","key":"10531_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13287-023-03470-w","volume":"14","author":"H Yang","year":"2023","unstructured":"Yang H, Yang Y, Kiskin FN, Shen M, Zhang JZ (2023) Recent advances in regulating the proliferation or maturation of human-induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther 14(1):228","journal-title":"Stem Cell Res Ther"},{"issue":"157","key":"10531_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113970","volume":"1","author":"K Zhu","year":"2023","unstructured":"Zhu K, Bao X, Wang Y, Lu T, Zhang L (2023) Human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte modelling of cardiovascular diseases for natural compound discovery. Biomed Pharmacother 1(157)","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10531_CR57","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nm.4087","volume":"22","author":"PW Burridge","year":"2016","unstructured":"Burridge PW, Li YF, Matsa E, Wu H, Ong SG, Sharma A et al (2016) Human induced pluripotent stem cell\u2013derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med 22(5):547\u2013556","journal-title":"Nat Med"},{"issue":"21","key":"10531_CR58","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","volume":"139","author":"T Kitani","year":"2019","unstructured":"Kitani T, Ong SG, Lam CK, Rhee JW, Zhang JZ, Oikonomopoulos A et al (2019) Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer. Circulation 139(21):2451\u20132465","journal-title":"Circulation"},{"issue":"8","key":"10531_CR59","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1161\/CIRCRESAHA.110.239574","volume":"108","author":"M Bauer","year":"2011","unstructured":"Bauer M, Cheng S, Jain M, Ngoy S, Theodoropoulos C, Trujillo A et al (2011) Echocardiographic Speckle-Tracking Based Strain Imaging for Rapid Cardiovascular Phenotyping in Mice. Circ Res 108(8):908\u2013916","journal-title":"Circ Res"},{"issue":"5","key":"10531_CR60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5):459\u2013465","journal-title":"Nat Med"},{"key":"10531_CR61","doi-asserted-by":"crossref","unstructured":"Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, et al. Coronary Microvascular Pericytes Are the Cellular Target of Sunitinib Malate\u2013Induced Cardiotoxicity. Sci Transl Med. 2013 May 29;5(187):187ra69\u2013187ra69.","DOI":"10.1126\/scitranslmed.3005066"},{"key":"10531_CR62","doi-asserted-by":"crossref","unstructured":"Zeiss CJ, Gatti DM, Toro-Salazar O, Davis C, Lutz CM, Spinale F, et al. Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans. G3 GenesGenomesGenetics. 2019 Aug 1;9(8):2637\u201346.","DOI":"10.1534\/g3.119.400232"},{"key":"10531_CR63","doi-asserted-by":"crossref","unstructured":"Gal \u00e1n AC, Lobo M, V \u00edlchez TJP, L \u00f3pez GJ, de MIA, P \u00e9rez MC, et al. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. J Am Coll Cardiol. 2019 Feb 26;73(7):779\u201391.","DOI":"10.1016\/j.jacc.2018.11.046"},{"key":"10531_CR64","doi-asserted-by":"crossref","unstructured":"Asnani A, Zheng B, Liu Y, Wang Y, Chen HH, Vohra A, et al. Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity. JCI Insight. 3(1):e96753.","DOI":"10.1172\/jci.insight.96753"},{"issue":"1","key":"10531_CR65","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-pharmtox-030620-104842","volume":"61","author":"KT Sawicki","year":"2021","unstructured":"Sawicki KT, Sala V, Prever L, Hirsch E, Ardehali H, Ghigo A (2021) Preventing and Treating Anthracycline Cardiotoxicity: New Insights. Annu Rev Pharmacol Toxicol 61(1):309\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10531_CR66","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/children11030378","volume":"11","author":"A Rique","year":"2024","unstructured":"Rique A, Cautela J, Thuny F, Michel G, Ovaert C, El Louali F (2024) Left Ventricular Longitudinal Strain Abnormalities in Childhood Exposure to Anthracycline Chemotherapy. Children 11(3):378","journal-title":"Children"},{"issue":"1","key":"10531_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0084-1","volume":"5","author":"HP Schultheiss","year":"2019","unstructured":"Schultheiss HP, Fairweather D, Caforio ALP, Escher F, Hershberger RE, Lipshultz SE et al (2019) Dilated cardiomyopathy. Nat Rev Dis Primer 5(1):1\u201319","journal-title":"Nat Rev Dis Primer"},{"issue":"4","key":"10531_CR68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","volume":"21","author":"T Shiga","year":"2020","unstructured":"Shiga T, Hiraide M (2020M) Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. Curr Treat Options Oncol 21(4):27","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10531_CR69","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/0284186X.2019.1711164","volume":"59","author":"A Dyhl-Polk","year":"2020","unstructured":"Dyhl-Polk A, Vaage-Nilsen M, Schou M, Vistisen KK, Lund CM, K\u00fcmler T et al (2020) Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. Acta Oncol 59(4):475\u2013483","journal-title":"Acta Oncol"},{"issue":"1","key":"10531_CR70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","volume":"134","author":"C Kosmas","year":"2008","unstructured":"Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N et al (2008) Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134(1):75\u201382","journal-title":"J Cancer Res Clin Oncol"},{"issue":"14","key":"10531_CR71","doi-asserted-by":"publisher","first-page":"1184523","DOI":"10.3389\/fphar.2023.1184523","volume":"15","author":"A Maslarinou","year":"2023","unstructured":"Maslarinou A, Manolopoulos VG, Ragia G (2023) Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? Front Pharmacol 15(14):1184523","journal-title":"Front Pharmacol"},{"issue":"2","key":"10531_CR72","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jaccao.2020.04.005","volume":"2","author":"I Raber","year":"2020","unstructured":"Raber I, Frazer MB, Zerillo JA, Asnani A (2020) Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants. JACC CardioOncology 2(2):329\u2013332","journal-title":"JACC CardioOncology"},{"issue":"4","key":"10531_CR73","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","volume":"21","author":"T Shiga","year":"2020","unstructured":"Shiga T, Hiraide M (2020) Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. Curr Treat Options Oncol 21(4):27","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"10531_CR74","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1517\/14740338.6.5.609","volume":"6","author":"NI Marupudi","year":"2007","unstructured":"Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6(5):609\u2013621","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10531_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2021.12.042","volume":"48","author":"A Chirca","year":"2022","unstructured":"Chirca A, Sanda NA, Mihalcea DJ, Vinereanu D, Costea RV (2022F 1) Taxane induced cardiotoxicity in a patient with breast cancer. Eur J Surg Oncol 48(2)","journal-title":"Eur J Surg Oncol"},{"key":"10531_CR76","doi-asserted-by":"crossref","unstructured":"Florescu M, Mihalcea D, Enescu OA, Radu E, Chirca A, Acasandrei AM, et al. Taxanes-induced cardiotoxicity is related to increased arterial stiffness and oxidative stress. Eur Heart J. 2013 Aug 1;34(suppl_1):P3006.","DOI":"10.1093\/eurheartj\/eht309.P3006"},{"issue":"22","key":"10531_CR77","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302\u20132313","journal-title":"N Engl J Med"},{"issue":"19","key":"10531_CR78","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al (2005) Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2\u2013Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group. J Clin Oncol 23(19):4265\u20134274","journal-title":"J Clin Oncol"},{"issue":"5","key":"10531_CR79","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1634\/theoncologist.2015-0424","volume":"21","author":"HD Long","year":"2016","unstructured":"Long HD, Lin YE, Zhang JJ, Zhong WZ, Zheng RN (2016) Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis. Oncologist 21(5):547\u2013554","journal-title":"Oncologist"},{"issue":"11","key":"10531_CR80","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","volume":"3","author":"MM Alhussein","year":"2021","unstructured":"Alhussein MM, Mokbel A, Cosman T, Aghel N, Yang EH, Mukherjee SD et al (2021) Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis. CJC Open 3(11):1372\u20131382","journal-title":"CJC Open"},{"issue":"1","key":"10531_CR81","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","volume":"33","author":"SD Lamore","year":"2020","unstructured":"Lamore SD, Kohnken RA, Peters MF, Kolaja KL (2020) Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches. Chem Res Toxicol 33(1):125\u2013136","journal-title":"Chem Res Toxicol"},{"issue":"23","key":"10531_CR82","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342","journal-title":"N Engl J Med"},{"issue":"25","key":"10531_CR83","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","volume":"379","author":"MM Gounder","year":"2018","unstructured":"Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA et al (2018D 20) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379(25):2417\u20132428","journal-title":"N Engl J Med"},{"issue":"5","key":"10531_CR84","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JVS et al (2007) Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma. Clin Cancer Res 13(5):1367\u20131373","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10531_CR85","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME et al (2011) Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. JNCI J Natl Cancer Inst 103(9):763\u2013773","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10531_CR86","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2020.08.033","volume":"323","author":"D Lobenwein","year":"2021","unstructured":"Lobenwein D, Kocher F, Dobner S, Gollmann-Tepek\u00f6yl\u00fc C, Holfeld J (2021) Cardiotoxic mechanisms of cancer immunotherapy \u2013 A systematic review. Int J Cardiol 323:179\u2013187","journal-title":"Int J Cardiol"},{"issue":"1","key":"10531_CR87","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373(1):23\u201334","journal-title":"N Engl J Med"},{"issue":"1","key":"10531_CR88","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H et al (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 4(1):50","journal-title":"J Immunother Cancer"},{"issue":"10027","key":"10531_CR89","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 387(10027):1540\u20131550","journal-title":"The Lancet"},{"issue":"99","key":"10531_CR90","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.lungcan.2016.06.025","volume":"1","author":"H Semper","year":"2016","unstructured":"Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Groh\u00e9 C (2016) Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer 1(99):117\u2013119","journal-title":"Lung Cancer"},{"issue":"10","key":"10531_CR91","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","volume":"9","author":"T Tadokoro","year":"2016","unstructured":"Tadokoro T, Keshino E, Makiyama A, Sasaguri T, Ohshima K, Katano H et al (2016) Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab. Circ Heart Fail 9(10)","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10531_CR92","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A (2020) Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc 9(2)","journal-title":"J Am Heart Assoc"},{"key":"10531_CR93","doi-asserted-by":"crossref","unstructured":"Safi M, Ahmed H, Al-Azab M, Xia Y long, Shan X, Al-radhi M, et al. (2021) PD-1\/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. J Adv Res. 29:45\u201354.","DOI":"10.1016\/j.jare.2020.09.006"},{"issue":"20","key":"10531_CR94","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer. N Engl J Med 377(20):1919\u20131929","journal-title":"N Engl J Med"},{"issue":"36","key":"10531_CR95","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768\u20132801","journal-title":"Eur Heart J"},{"issue":"1","key":"10531_CR96","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","volume":"1","author":"PS Hall","year":"2013","unstructured":"Hall PS, Harshman LC, Srinivas S, Witteles RM (2013) The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC Heart Fail 1(1):72\u201378","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10531_CR97","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/jcpt.12124","volume":"39","author":"S Limat","year":"2014","unstructured":"Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S et al (2014) Incidence and risk-factors of CHOP\/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin\u2019s lymphoma. J Clin Pharm Ther 39(2):168\u2013174","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"10531_CR98","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1002\/ehf2.14045","volume":"9","author":"A Lalario","year":"2022","unstructured":"Lalario A, Del Mestre E, Lo Casto M, Nuzzi V, Manca P, Bromage DI et al (2022) Clinical characterization and natural history of chemotherapy-induced dilated cardiomyopathy. ESC Heart Fail 9(5):3052\u20133059","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10531_CR99","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2174\/157340311799960681","volume":"7","author":"A Saidi","year":"2011","unstructured":"Saidi A, Alharethi R (2011) Management of chemotherapy induced cardiomyopathy. Curr Cardiol Rev 7(4):245\u2013249","journal-title":"Curr Cardiol Rev"},{"issue":"5","key":"10531_CR100","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/OP.20.00924","volume":"17","author":"JR Stone","year":"2021","unstructured":"Stone JR, Kanneganti R, Abbasi M, Akhtari M (2021M) Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations. JCO Oncol Pract 17(5):228\u2013236","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"10531_CR101","first-page":"863","volume":"32","author":"R Moudgil","year":"2016","unstructured":"Moudgil R, Yeh ETH (2016) Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. Can J Cardiol 32(7):863-870.e5","journal-title":"Can J Cardiol"},{"issue":"9","key":"10531_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.847012","volume":"15","author":"MB Morelli","year":"2022","unstructured":"Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M et al (2022) Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Front Cardiovasc Med 15(9)","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10531_CR103","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/phar.2638","volume":"41","author":"JA Veeder","year":"2021","unstructured":"Veeder JA, Hothem LN, Cipriani AE, Jensen BC, Rodgers JE (2021) Chemotherapy-associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies. Pharmacother J Hum Pharmacol Drug Ther 41(12):1066\u20131080","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"1","key":"10531_CR104","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/clpt.2013.201","volume":"95","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh E (2014) Topoisomerase 2\u03b2: A Promising Molecular Target for Primary Prevention of Anthracycline-Induced Cardiotoxicity. Clin Pharmacol Ther 95(1):45\u201352","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10531_CR105","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF et al (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18(11):1639\u20131642","journal-title":"Nat Med"},{"issue":"3","key":"10531_CR106","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","volume":"7","author":"K Nakano","year":"2001","unstructured":"Nakano K, Vousden KH (2001M 1) PUMA, a Novel Proapoptotic Gene, Is Induced by p53. Mol Cell 7(3):683\u2013694","journal-title":"Mol Cell"},{"issue":"11","key":"10531_CR107","first-page":"2435","volume":"20","author":"DX Zhang","year":"2016","unstructured":"Zhang DX, Ma DY, Yao ZQ, Fu CY, Shi YX, Wang QL et al (2016J) ERK1\/2\/p53 and NF-\u03baB dependent-PUMA activation involves in doxorubicin-induced cardiomyocyte apoptosis. Eur Rev Med Pharmacol Sci 20(11):2435\u20132442","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"10531_CR108","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/febs.14186","volume":"285","author":"A Pe\u00f1a-Blanco","year":"2018","unstructured":"Pe\u00f1a-Blanco A, Garc\u00eda-S\u00e1ez AJ (2018) Bax, Bak and beyond \u2014 mitochondrial performance in apoptosis. FEBS J 285(3):416\u2013431","journal-title":"FEBS J"},{"issue":"3","key":"10531_CR109","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1124\/jpet.108.146423","volume":"328","author":"J Niu","year":"2009","unstructured":"Niu J, Azfer A, Wang K, Wang X, Kolattukudy PE (2009) Cardiac-targeted expression of soluble fas attenuates doxorubicin-induced cardiotoxicity in mice. J Pharmacol Exp Ther 328(3):740\u2013748","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10531_CR110","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000512771","volume":"146","author":"EV Grakova","year":"2021","unstructured":"Grakova EV, Shilov SN, Kopeva KV, Berezikova EN, Popova AA, Neupokoeva MN et al (2021) Anthracycline-Induced Cardiotoxicity: The Role of Endothelial Dysfunction. Cardiology 146(3):315\u2013323","journal-title":"Cardiology"},{"issue":"10","key":"10531_CR111","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.7150\/ijbs.7502","volume":"9","author":"P Rajendran","year":"2013","unstructured":"Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G et al (2013) The Vascular Endothelium and Human Diseases. Int J Biol Sci 9(10):1057\u20131069","journal-title":"Int J Biol Sci"},{"issue":"237","key":"10531_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108116","volume":"1","author":"JD Terwoord","year":"2022","unstructured":"Terwoord JD, Beyer AM, Gutterman DD (2022) Endothelial dysfunction as a complication of anti-cancer therapy. Pharmacol Ther 1(237)","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10531_CR113","doi-asserted-by":"publisher","first-page":"C645","DOI":"10.1152\/ajpcell.00186.2012","volume":"303","author":"AR Ludke","year":"2012","unstructured":"Ludke AR, Sharma AK, Akolkar G, Bajpai G, Singal PK (2012) Downregulation of vitamin C transporter SVCT-2 in doxorubicin-induced cardiomyocyte injury. Am J Physiol-Cell Physiol 303(6):C645\u2013C653","journal-title":"Am J Physiol-Cell Physiol"},{"issue":"2","key":"10531_CR114","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Prasad SVN et al (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124(2):617\u2013630","journal-title":"J Clin Invest"},{"key":"10531_CR115","doi-asserted-by":"crossref","unstructured":"Muckenthaler MU, Galy B, Hentze MW (2008) Systemic Iron Homeostasis and the Iron-Responsive Element\/Iron-Regulatory Protein (IRE\/IRP) Regulatory Network. Annu Rev Nutr. 28:197\u2013213.","DOI":"10.1146\/annurev.nutr.28.061807.155521"},{"issue":"1","key":"10531_CR116","doi-asserted-by":"publisher","first-page":"H37","DOI":"10.1152\/ajpheart.01057.2004","volume":"289","author":"M Tokarska-Schlattner","year":"2005","unstructured":"Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T et al (2005) Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol-Heart Circ Physiol 289(1):H37-47","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"1","key":"10531_CR117","doi-asserted-by":"publisher","first-page":"11989","DOI":"10.1038\/s41598-017-12095-y","volume":"7","author":"L Huang","year":"2017","unstructured":"Huang L, Zhang K, Guo Y, Huang F, Yang K, Chen L et al (2017) Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts. Sci Rep 7(1):11989","journal-title":"Sci Rep"},{"issue":"179","key":"10531_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117312","volume":"1","author":"H Li","year":"2024","unstructured":"Li H, Wang M, Huang Y (2024) Anthracycline-induced cardiotoxicity: An overview from cellular structural perspective. Biomed Pharmacother 1(179)","journal-title":"Biomed Pharmacother"},{"issue":"Suppl 1","key":"10531_CR119","first-page":"1","volume":"10","author":"CE Rupert","year":"2015","unstructured":"Rupert CE, Coulombe KL (2015A 8) The Roles of Neuregulin-1 in Cardiac Development, Homeostasis, and Disease. Biomark Insights 10(Suppl 1):1\u20139","journal-title":"Biomark Insights"},{"issue":"6","key":"10531_CR120","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/bjc.2014.79","volume":"110","author":"MM Wattenberg","year":"2014","unstructured":"Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW (2014) Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. Br J Cancer 110(6):1472\u20131480","journal-title":"Br J Cancer"},{"issue":"8","key":"10531_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.694711","volume":"27","author":"PY Hsu","year":"2021","unstructured":"Hsu PY, Mammadova A, Benkirane-Jessel N, D\u00e9saubry L, Nebigil CG (2021) Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies. Front Cardiovasc Med 27(8)","journal-title":"Front Cardiovasc Med"},{"issue":"153","key":"10531_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2023.107223","volume":"1","author":"S Barachini","year":"2023","unstructured":"Barachini S, Ghelardoni S, Varga ZV, Mehanna RA, Montt-Guevara MM, Ferdinandy P et al (2023) Antineoplastic drugs inducing cardiac and vascular toxicity \u2013 An update. Vascul Pharmacol 1(153)","journal-title":"Vascul Pharmacol"},{"issue":"3","key":"10531_CR123","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s13273-018-0027-z","volume":"14","author":"WS Lee","year":"2018","unstructured":"Lee WS, Kim J (2018) Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy. Mol Cell Toxicol 14(3):247\u2013254","journal-title":"Mol Cell Toxicol"},{"issue":"153","key":"10531_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113280","volume":"1","author":"H Jiang","year":"2022","unstructured":"Jiang H, Wang C, Zhang A, Li Y, Li J, Li Z et al (2022) ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis. Biomed Pharmacother 1(153)","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"10531_CR125","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41569-024-01056-4","volume":"21","author":"JWS Jahng","year":"2024","unstructured":"Jahng JWS, Little MP, No HJ, Loo BW, Wu JC (2024) Consequences of ionizing radiation exposure to the cardiovascular system. Nat Rev Cardiol 21(12):880\u2013898","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"10531_CR126","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fcvm.2020.00041","volume":"20","author":"SM Mrotzek","year":"2020","unstructured":"Mrotzek SM, Rassaf T, Totzeck M (2020) Cardiovascular Damage Associated With Chest Irradiation. Front Cardiovasc Med 20(7):41","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10531_CR127","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.ahj.2004.12.026","volume":"150","author":"PA Heidenreich","year":"2005","unstructured":"Heidenreich PA, Hancock SL, Vagelos RH, Lee BK, Schnittger I (2005) Diastolic dysfunction after mediastinal irradiation. Am Heart J 150(5):977\u2013982","journal-title":"Am Heart J"},{"issue":"1","key":"10531_CR128","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13058-020-1249-2","volume":"22","author":"AK Wennstig","year":"2020","unstructured":"Wennstig AK, Wadsten C, Garmo H, Fredriksson I, Blomqvist C, Holmberg L et al (2020) Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort. Breast Cancer Res 22(1):10","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10531_CR129","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.ijrobp.2007.05.034","volume":"69","author":"CW Taylor","year":"2007","unstructured":"Taylor CW, Nisbet A, McGale P, Darby SC (2007) Cardiac Exposures in Breast Cancer Radiotherapy: 1950s\u20131990s. Int J Radiat Oncol 69(5):1484\u20131495","journal-title":"Int J Radiat Oncol"},{"issue":"9","key":"10531_CR130","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00066-016-1011-y","volume":"192","author":"M Becker-Schiebe","year":"2016","unstructured":"Becker-Schiebe M, Stockhammer M, Hoffmann W, Wetzel F, Franz H (2016) Does mean heart dose sufficiently reflect coronary artery exposure in left-sided breast cancer radiotherapy? Strahlenther Onkol 192(9):624\u2013631","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"10531_CR131","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ijrobp.2023.03.045","volume":"119","author":"JE Bates","year":"2024","unstructured":"Bates JE, Rancati T, Keshavarz H, Gagliardi G, Aznar MC, Howell RM et al (2024) Cardiac Disease in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. Int J Radiat Oncol 119(2):522\u2013532","journal-title":"Int J Radiat Oncol"},{"issue":"11","key":"10531_CR132","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Br\u00f8nnum D et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368(11):987\u2013998","journal-title":"N Engl J Med"},{"issue":"1","key":"10531_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00066-018-1378-z","volume":"195","author":"MD Piroth","year":"2019","unstructured":"Piroth MD, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R et al (2019) Heart toxicity from breast cancer radiotherapy: Current findings, assessment, and prevention. Strahlenther Onkol 195(1):1","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"10531_CR134","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/bjc.2012.575","volume":"108","author":"KE Henson","year":"2013","unstructured":"Henson KE, McGale P, Taylor C, Darby SC (2013) Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer 108(1):179\u2013182","journal-title":"Br J Cancer"},{"key":"10531_CR135","doi-asserted-by":"crossref","unstructured":"Koutroumpakis E, Deswal A, Yusuf SW, Abe J ichi, Nead KT, Potter AS, et al. Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment. Curr Oncol Rep. 2022 May 1;24(5):543\u201353.","DOI":"10.1007\/s11912-022-01238-8"},{"issue":"1","key":"10531_CR136","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejphar.2012.06.037","volume":"692","author":"HH Mansour","year":"2012","unstructured":"Mansour HH, Tawfik SS (2012) Early treatment of radiation-induced heart damage in rats by caffeic acid phenethyl ester. Eur J Pharmacol 692(1):46\u201351","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10531_CR137","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00392-021-01809-y","volume":"110","author":"M S\u00e1rk\u00f6zy","year":"2021","unstructured":"S\u00e1rk\u00f6zy M, Varga Z, G\u00e1sp\u00e1r R, Sz\u0171cs G, Kov\u00e1cs MG, Kov\u00e1cs ZZA et al (2021) Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside. Clin Res Cardiol 110(4):507\u2013531","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"10531_CR138","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/COC.0000000000000815","volume":"44","author":"RR Sarkar","year":"2021","unstructured":"Sarkar RR, Hatamipour A, Panjwani N, Courtney PT, Cherry DR, Salans MA et al (2021) Impact of Radiation on Cardiovascular Outcomes in Older Resectable Esophageal Cancer Patients With Medicare. Am J Clin Oncol 44(6):275","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10531_CR139","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00018-018-2956-z","volume":"76","author":"B Baselet","year":"2019","unstructured":"Baselet B, Sonveaux P, Baatout S, Aerts A (2019) Pathological effects of ionizing radiation: endothelial activation and dysfunction. Cell Mol Life Sci 76(4):699\u2013728","journal-title":"Cell Mol Life Sci"},{"key":"10531_CR140","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Gavela AA, Figueiras-Graillet L, Luis \u00c1M, Salas Segura J, Ci\u00e9rvide R, del Cerro Pe\u00f1alver E, et al. Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies. Cancers. 2021 13(7):1712.","DOI":"10.3390\/cancers13071712"},{"issue":"1","key":"10531_CR141","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms23010441","volume":"23","author":"A Choksey","year":"2022","unstructured":"Choksey A, Timm KN (2022) Cancer Therapy-Induced Cardiotoxicity\u2014A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy. Int J Mol Sci 23(1):441","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10531_CR142","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12967-023-04554-0","volume":"21","author":"Z Yu","year":"2023","unstructured":"Yu Z, Xu C, Song B, Zhang S, Chen C, Li C et al (2023) Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances. J Transl Med 21(1):708","journal-title":"J Transl Med"},{"issue":"18","key":"10531_CR143","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021686","volume":"10","author":"E Belzile-Dugas","year":"2021","unstructured":"Belzile-Dugas E, Eisenberg MJ (2021) Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology. J Am Heart Assoc 10(18)","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10531_CR144","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.repc.2021.04.011","volume":"41","author":"JC Toste","year":"2022","unstructured":"Toste JC (2022) Cardio-oncology: Understanding the different mechanisms of cardiovascular toxicity. Rev Port Cardiol 41(7):587\u2013597","journal-title":"Rev Port Cardiol"},{"issue":"5","key":"10531_CR145","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","volume":"167","author":"MG Kaya","year":"2013","unstructured":"Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M et al (2013) Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study. Int J Cardiol 167(5):2306\u20132310","journal-title":"Int J Cardiol"},{"issue":"1","key":"10531_CR146","first-page":"1","volume":"10","author":"FF Gong","year":"2024","unstructured":"Gong FF, Grunblatt E, Voss WB, Rangarajan V, Raissi S, Chow K et al (2024D) A strain-guided trial of cardioprotection in early-stage breast cancer patients on anti-HER2 therapy (PROTECT HER2). Cardio-Oncol 10(1):1\u201311","journal-title":"Cardio-Oncol"},{"key":"10531_CR147","doi-asserted-by":"crossref","unstructured":"Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013 Jan 28;346(jan28 1):f360\u2013f360.","DOI":"10.1136\/bmj.f360"},{"issue":"11","key":"10531_CR148","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27308","volume":"65","author":"V Gupta","year":"2018","unstructured":"Gupta V, Kumar Singh S, Agrawal V, Bali ST (2018) Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial. Pediatr Blood Cancer 65(11)","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10531_CR149","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","volume":"17","author":"G Janbabai","year":"2017","unstructured":"Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J (2017) Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy. Cardiovasc Toxicol 17(2):130\u2013139","journal-title":"Cardiovasc Toxicol"},{"issue":"11","key":"10531_CR150","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/cncr.21478","volume":"104","author":"H Nakamae","year":"2005","unstructured":"Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K et al (2005) Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104(11):2492\u20132498","journal-title":"Cancer"},{"issue":"1","key":"10531_CR151","first-page":"1","volume":"5","author":"S Ganatra","year":"2019","unstructured":"Ganatra S, Nohria A, Shah S, Groarke JD, Sharma A, Venesy D et al (2019) Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncol 5(1):1","journal-title":"Cardio-Oncol"},{"issue":"8","key":"10531_CR152","first-page":"259","volume":"9","author":"C Kourek","year":"2022","unstructured":"Kourek C, Touloupaki M, Rempakos A, Loritis K, Tsougkos E, Paraskevaidis I et al (2022) Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review. J Cardiovasc Dev Dis 9(8):259","journal-title":"J Cardiovasc Dev Dis"},{"key":"10531_CR153","doi-asserted-by":"publisher","unstructured":"Strauss MH, Hall AS, The NK, Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases. Cardiovasc Drugs Ther [Internet]. (2021) cited 2023 Jul 11. Available from: https:\/\/doi.org\/10.1007\/s10557-021-07248-1","DOI":"10.1007\/s10557-021-07248-1"},{"issue":"21","key":"10531_CR154","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671\u20131680","journal-title":"Eur Heart J"},{"issue":"25","key":"10531_CR155","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","volume":"143","author":"SL Heck","year":"2021","unstructured":"Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW et al (2021) Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2\u00d72 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation 143(25):2431\u20132440","journal-title":"Circulation"},{"issue":"8","key":"10531_CR156","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ et al (2017) Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101\u2013Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol 35(8):870\u2013877","journal-title":"J Clin Oncol"},{"issue":"23","key":"10531_CR157","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","volume":"60","author":"S Seicean","year":"2012","unstructured":"Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH (2012) Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline Chemotherapy. J Am Coll Cardiol 60(23):2384\u20132390","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10531_CR158","first-page":"153","volume":"35","author":"O Calvillo-Arg\u00fcelles","year":"2019","unstructured":"Calvillo-Arg\u00fcelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S, Amir E et al (2019) Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Can J Cardiol 35(2):153\u2013159","journal-title":"Can J Cardiol"},{"key":"10531_CR159","unstructured":"American College of Cardiology [Internet]. [cited 2025 Jan 24]. Statins For Cardioprotection From Anthracycline Cardiotoxicity. Available from: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2023\/09\/07\/12\/43\/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2023%2f09%2f07%2f12%2f43%2fStatins-For-Cardioprotection-From-Anthracycline-Cardiotoxicity"},{"key":"10531_CR160","doi-asserted-by":"crossref","unstructured":"Kim JW. Cutting-edge technologies in external radiation therapy. Ewha Med J [Internet]. 2024 Oct 31 [cited 2025 Jan 4];47(4). Available from: https:\/\/synapse.koreamed.org\/articles\/1516088857","DOI":"10.12771\/emj.2024.e59"},{"issue":"4","key":"10531_CR161","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jaccao.2024.04.009","volume":"6","author":"SL Busschaert","year":"2024","unstructured":"Busschaert SL, Kimpe E, Gevaert T, De Ridder M, Putman K (2024) Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy: A Balance Between Side Effects and Costs. JACC CardioOncology 6(4):514\u2013525","journal-title":"JACC CardioOncology"},{"key":"10531_CR162","doi-asserted-by":"crossref","unstructured":"Mader T, Pace R, Boucas da Silva RT, Erwin Johannes Adam L, N\u00e4f G, Charles Winter C et al (2024) Deep inspirational breast hold (DIBH) for right breast irradiation: Improved sparing of liver and lung tissue. Clin Transl Radiat Oncol. 45","DOI":"10.1016\/j.ctro.2024.100731"},{"issue":"7","key":"10531_CR163","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s12012-021-09644-3","volume":"21","author":"AZ Ahmed","year":"2021","unstructured":"Ahmed AZ, Mumbrekar KD, Satyam SM, Shetty P, D\u2019Souza MR, Singh VK (2021) Chia Seed Oil Ameliorates Doxorubicin-Induced Cardiotoxicity in Female Wistar Rats: An Electrocardiographic. Biochemical and Histopathological Approach Cardiovasc Toxicol 21(7):533\u2013542","journal-title":"Biochemical and Histopathological Approach Cardiovasc Toxicol"},{"key":"10531_CR164","doi-asserted-by":"crossref","unstructured":"Abdelghffar EA, Obaid WA, Mohammedsaleh ZM, Ouchari W, Eldahshan OA, Sobeh M. (2022) Ajwa dates (Phoenix dactylifera L.) attenuate cisplatin-induced nephrotoxicity in rats via augmenting Nrf2, modulating NADPH oxidase-4 and mitigating inflammatory\/apoptotic mediators. Biomed Pharmacother. 156:113836.","DOI":"10.1016\/j.biopha.2022.113836"},{"issue":"18","key":"10531_CR165","doi-asserted-by":"publisher","first-page":"153473541986235","DOI":"10.1177\/1534735419862351","volume":"1","author":"S Al-Jaouni","year":"2019","unstructured":"Al-Jaouni S, Abdul-Hady S, El-Bassossy H, Salah N, Hagras M (2019) Ajwa Nanopreparation Prevents Doxorubicin-Associated Cardiac Dysfunction: Effect on Cardiac Ischemia and Antioxidant Capacity. Integr Cancer Ther 1(18):1534735419862351","journal-title":"Integr Cancer Ther"},{"key":"10531_CR166","doi-asserted-by":"crossref","unstructured":"Khan F, Khan TJ, Kalamegam G, Pushparaj PN, Chaudhary A, Abuzenadah A, et al. (2017) Anti-cancer effects of Ajwa dates (Phoenix dactylifera L.) in diethylnitrosamine induced hepatocellular carcinoma in Wistar rats. BMC Complement Altern Med. 17:418.","DOI":"10.1186\/s12906-017-1926-6"},{"issue":"8","key":"10531_CR167","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3390\/pharmaceutics16081105","volume":"16","author":"FS Arruda","year":"2024","unstructured":"Arruda FS, Tom\u00e9 FD, Milhomem AC, Franco PIR, Justino AB, Franco RR et al (2024) Curcumin Attenuates Doxorubicin-Induced Cardiac Oxidative Stress and Increases Survival in Mice. Pharmaceutics 16(8):1105","journal-title":"Pharmaceutics"},{"issue":"3","key":"10531_CR168","doi-asserted-by":"publisher","first-page":"74","DOI":"10.31083\/j.rcm2503074","volume":"25","author":"H Shi","year":"2024","unstructured":"Shi H, Duan L, Tong L, Pu P, Wei L, Wang L et al (2024) Research Progress on Flavonoids in Traditional Chinese Medicine to Counteract Cardiotoxicity Associated with Anti-Tumor Drugs. Rev Cardiovasc Med 25(3):74","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"10531_CR169","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2119\/molmed.2014.00261","volume":"21","author":"E Hao","year":"2015","unstructured":"Hao E, Mukhopadhyay P, Cao Z, Erd\u00e9lyi K, Holovac E, Liaudet L et al (2015) Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis. Mol Med 21(1):38\u201345","journal-title":"Mol Med"},{"issue":"2","key":"10531_CR170","doi-asserted-by":"publisher","first-page":"168","DOI":"10.21608\/bfszu.2023.245303.1335","volume":"2024","author":"KAEH Mohammed","year":"2024","unstructured":"Mohammed KAEH, Soliman NA, Eldahmy SI, Shalaby A (2024) Eventual Medicinal Benefits of Cannabidiol Oil alleviates Doxorubicin-Related Cardiac injuries. Bull Fac Sci Zagazig Univ 2024(2):168\u2013173","journal-title":"Bull Fac Sci Zagazig Univ"},{"key":"10531_CR171","doi-asserted-by":"crossref","unstructured":"Morishita S, Hamaue Y, Fukushima T, Tanaka T, Fu JB, Nakano J (2020) Effect of Exercise on Mortality and Recurrence in Patients With Cancer: A Systematic Review and Meta-Analysis. Integr Cancer Ther 1(19):1534735420917462","DOI":"10.1177\/1534735420917462"},{"issue":"6","key":"10531_CR172","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.clbc.2023.04.010","volume":"23","author":"YL Tsai","year":"2023","unstructured":"Tsai YL, Chuang YC, Chen CP, Lee YC, Cheng YY, Ou-Yang LJ (2023A 1) Feasibility of Aerobic Exercise Training to Mitigate Cardiotoxicity of Breast Cancer Therapy: A Systematic Review and Meta-Analysis. Clin Breast Cancer 23(6):576\u2013590","journal-title":"Clin Breast Cancer"},{"key":"10531_CR173","doi-asserted-by":"publisher","first-page":"155982762413043","DOI":"10.1177\/15598276241304373","volume":"6","author":"SD D\u2019Andre","year":"2024","unstructured":"D\u2019Andre SD, Ellsworth LL, Kirsch JL, Montane HN, Kruger MB, Donovan KA et al (2024D) Cancer and Stress: Understanding the Connections and Interventions. Am J Lifestyle Med 6:15598276241304372","journal-title":"Am J Lifestyle Med"},{"issue":"9","key":"10531_CR174","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1751-7176.2011.00518.x","volume":"13","author":"AA Taylor","year":"2011","unstructured":"Taylor AA, Siragy H, Nesbitt S (2011) Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety. J Clin Hypertens 13(9):677\u2013686","journal-title":"J Clin Hypertens"},{"issue":"8","key":"10531_CR175","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/life12081183","volume":"12","author":"V Sorodoc","year":"2022","unstructured":"Sorodoc V, Sirbu O, Lionte C, Haliga RE, Stoica A, Ceasovschih A et al (2022) The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity. Life 12(8):1183","journal-title":"Life"},{"issue":"4","key":"10531_CR176","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V et al (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21(4):519\u2013530","journal-title":"Lancet Oncol"},{"issue":"4","key":"10531_CR177","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1634\/theoncologist.2015-0321","volume":"21","author":"AF Yu","year":"2016","unstructured":"Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M et al (2016) Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Oncologist 21(4):418\u2013424","journal-title":"Oncologist"},{"issue":"1","key":"10531_CR178","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5603\/RPOR.a2021.0124","volume":"27","author":"S Tamilarasu","year":"2022","unstructured":"Tamilarasu S, Saminathan M (2022) Dosimetric comparison of normal breathing and deep inspiration breath hold technique for synchronous bilateral breast cancer using 6MV flattened beam and flattening filter free beam. Rep Pract Oncol Radiother 27(1):63\u201375","journal-title":"Rep Pract Oncol Radiother"},{"issue":"10","key":"10531_CR179","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1080\/0284186X.2018.1490027","volume":"57","author":"K Wikstr\u00f6m","year":"2018","unstructured":"Wikstr\u00f6m K, Isacsson U, Nilsson K, Ahnesj\u00f6 A (2018) Reproducibility of heart and thoracic wall position in repeated deep inspiration breath holds for radiotherapy of left-sided breast cancer patients. Acta Oncol 57(10):1318\u20131324","journal-title":"Acta Oncol"},{"issue":"2","key":"10531_CR180","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s12282-019-01023-9","volume":"27","author":"J Lai","year":"2020","unstructured":"Lai J, Hu S, Luo Y, Zheng R, Zhu Q, Chen P et al (2020) Meta-analysis of deep inspiration breath hold (DIBH) versus free breathing (FB) in postoperative radiotherapy for left-side breast cancer. Breast Cancer 27(2):299\u2013307","journal-title":"Breast Cancer"},{"issue":"6","key":"10531_CR181","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.prro.2015.06.002","volume":"5","author":"SK Tanguturi","year":"2015","unstructured":"Tanguturi SK, Lyatskaya Y, Chen Y, Catalano PJ, Chen MH, Yeo WP et al (2015) Prospective assessment of deep inspiration breath-hold using 3-dimensional surface tracking for irradiation of left-sided breast cancer. Pract Radiat Oncol 5(6):358\u2013365","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10531_CR182","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12672-023-00636-z","volume":"14","author":"N Salim","year":"2023","unstructured":"Salim N, Popodko A, Tumanova K, Stolbovoy A, Lagkueva I, Ragimov V (2023) Cardiac dose in the treatment of synchronous bilateral breast cancer patients between three different radiotherapy techniques (VMAT, IMRT, and 3D CRT). Discov Oncol 14(1):29","journal-title":"Discov Oncol"},{"issue":"5","key":"10531_CR183","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/bioengineering9050213","volume":"9","author":"PY Hou","year":"2022","unstructured":"Hou PY, Hsieh CH, Wu LJ, Hsu CX, Kuo DY, Lu YF et al (2022) Cardiac Function after Modern Radiation Therapy with Volumetric Modulated Arc Therapy or Helical Tomotherapy for Advanced Left-Breast Cancer Receiving Regional Nodal Irradiation. Bioengineering 9(5):213","journal-title":"Bioengineering"},{"key":"10531_CR184","doi-asserted-by":"crossref","unstructured":"Loap P, Fourquet A, Kirova Y (2021) Evaluation of Cardiac Conduction System Exposure with Breast Volumetric Modulated Arc Therapy and Intensity Modulated Proton Therapy. Int J Radiat Oncol. 111(3)","DOI":"10.1016\/j.ijrobp.2021.07.773"},{"issue":"7","key":"10531_CR185","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1249\/MSS.0b013e3181e0c112","volume":"42","author":"KH Schmitz","year":"2010","unstructured":"Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galv\u00e3o DA, Pinto BM et al (2010) American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors. Med Sci Sports Exerc 42(7):1409\u20131426","journal-title":"Med Sci Sports Exerc"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10531-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10531-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10531-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:54:04Z","timestamp":1757188444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10531-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":185,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["10531"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10531-0","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"21 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}